| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
From the Laboratory of Experimental Angiogenesis,* Sigma Tau, Rome; the Laboratories of Molecular and Cell Biology and Molecular Oncology, Istituto Dermopatico dell’Immacolata-Istituto di Ricovero e Cura a Carattere Scientifico, Rome; the Anatomic Pathology Institute, Tor Vergata University, Rome; and the Laboratory of Vascular Biology and Gene Therapy,¶ Centro Cardiologico Monzino–Istituto di Ricovero e Cura a Carattere Scientifico, Milan, Italy
 |
Abstract |
|---|
 Top Abstract Materials and MethodsResultsDiscussionReferences |
|---|
Among the growth factors implicated in tumor angiogenesis, a major contribution has been ascribed to vascular endothelial growth factor (VEGF).3 In addition to the proliferative and anti-apoptotic action on endothelial cells, VEGF directly promotes proliferation and/or migration of VEGF receptor-expressing tumor cells.4-6 VEGF and its receptors are also involved in mobilization of endothelial and hematopoietic stem cells (HSCs) from the bone marrow and their recruitment at the tumor site where they contribute to tumor angiogenesis.2,7 Although VEGF and its receptor-2 (VEGFR-2) were previously considered major targets for the therapeutic inhibition of angiogenesis, a significant role of VEGF receptor-1 (VEGFR-1) in modulation of angiogenesis has been reported.8 VEGFR-1 has been shown to be involved in tissue-specific localization and growth of tumor metastases.9,10 Besides VEGF, other members of the VEGF family, in particular placenta growth factor (PlGF) and VEGF-B, bind to VEGFR-1, but their relative role in VEGFR-1 activation is still undefined.
PlGF plays an important function in adult pathological angiogenesis, whereas it is redundant for the development of the embryonic vasculature.11 PlGF is chemotactic for monocytes12 and can restore early and late phases of hematopoiesis after bone marrow suppression through chemotaxis of progenitor cells.13 PlGF also acts on VEGFR-1-expressing smooth muscle cells and pericytes, thus promoting vessel maturation. In fact, PlGF-deficient mice display less mature vessels compared to wild-type (WT) controls.11 Besides directly activating its tyrosine kinase receptor, PlGF sustains VEGF activity, probably through increased phosphorylation of VEGFR-2.14
Regarding the contribution to tumor angiogenesis, PlGF expression has been detected in human tumor cells both in vitro and in vivo and is up-regulated during tumor progression.6,15,16 Moreover, tumor growth and angiogenesis are markedly reduced in PlGF-deficient mice,11 and overexpression of PlGF in glioma cells leads to increased tumor growth and endothelial cell survival.17 On the other hand, PlGF could play a negative role in tumor angiogenesis through the formation of PlGF/VEGF heterodimers. These heterodimers are naturally produced by normal and tumor cells in culture,18-20 binding and activating VEGFR-2, although with reduced affinity compared to VEGF homodimers. Therefore, some authors suggest that the expression of PlGF in tumor tissue could result in inhibition of VEGF-mediated tumor angiogenesis because of the augmented formation of less active PlGF/VEGF heterodimers and the depletion of VEGF homodimers.21
We have previously shown that PlGF overexpression in the skin, under the control of a keratin 14 promoter cassette (K14-PlGF mice), results in a substantial increase in number, branching, and size of dermal blood vessels.22 Mature smooth muscle-coated vessels are abundant in the K14-PlGF mice. High levels of PlGF homodimers are produced by keratinocytes of transgenic mice whereas homodimeric VEGF is significantly reduced compared with control littermates. Therefore, this murine model represents a valuable tool to investigate the effect of PlGF in the biology of tumor growth and tumor-host interactions.
In this study, we injected syngeneic murine melanoma cells in K14-PlGF transgenic mice and matched controls. Using this approach, we could demonstrate that PlGF transgenic animals substantially differ from WT littermates in melanoma growth rate, tumor vascularization, and metastasis formation.
|
Materials and Methods |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
B16-BL6 murine melanoma cell line was maintained in Dulbecco’s modified Eagle’s medium (Invitrogen, Carlsbad, CA) supplemented with 2 mmol/L glutamine, 10% fetal calf serum (Hyclone Laboratories, Logan, UT), and antibiotics. Human umbilical vein endothelial cells (HUVECs) were isolated from freshly delivered umbilical cords as previously described23 and cultured in Endothelial Cell Growth Medium-2 kit from Clonetics (BioWhittaker Inc., Walkersville, MD). The human melanoma cell line M146 was maintained in RPMI 1640 medium supplemented with glutamine, fetal calf serum, and antibiotics as described for the B16-BL6 cells. Human fibroblasts were isolated as previously described24 and cultured in Dulbecco’s modified Eagle’s medium. The human fibroblast-conditioned medium was obtained from subconfluent cultures incubated for 24 hours in medium without serum, supplemented with 0.1% bovine serum albumin. Recombinant mouse PlGF-2 (rmPlGF) and VEGF (rmVEGF) were purchased from R&D Systems (Minneapolis, MN).
Mice
Transgenic lines were established on a B6D2F1 background as previously described.22
All mice were treated in accordance with the institutional guidelines for the care of experimental animals. For tumor implantation, mice were anesthetized by intraperitoneal injection of 15 µl/g 2.5% 2,2,2-tribromoethyl alcohol (Sigma-Aldrich, Milwaukee, WI). B16-BL6 cells (1 x 106) in 50 µl of Ca2+/Mg2+-free Hanks’ balanced salt solution (ICN Biomedicals Inc., Aurora, OH) were inoculated intradermally in the right flanks of mice by using a 100-µl Hamilton syringe. Tumor attachment rate was 100%; tumor growth was followed daily and measured by a digital caliper. Tumor volume (V) was calculated as V = 
/6xab2, where a is the longer and b is the shorter of two perpendicular tumor diameters. Mice were sacrificed 25 days after cell inoculation. Animals were necropsied, and organs were examined for the presence of macroscopic metastases. Tumors and lungs were then processed for histological analysis. For lung colonization assay, 1.5 x 104 B16-BL6 cells in 100 µl of Hanks’ balanced salt solution were injected into the lateral tail vein. The animals were sacrificed 15 days after inoculation. The lungs were removed and processed for histological analysis.
Histology and Immunohistochemistry
Four-µm-thick paraformaldehyde-fixed, paraffin-embedded tumor or lung sections were used, and specimens were deparaffinized, rehydrated, and processed as previously described.20
Hematoxylin and eosin (H&E) staining was performed by standard procedures. The antibodies used for blood vessel immunohistochemistry were an anti-mouse PECAM/CD31 polyclonal antibody (M-20; Santa Cruz Biotechnology, Santa Cruz, CA) used at a concentration of 2 µg/ml for 2 hours at 37°C and an anti-
-smooth muscle actin (-SMA) monoclonal antibody (clone 144, Sigma-Aldrich) diluted 1:30, for 1 hour at room temperature. Negative controls were done by omitting the primary antibody. To detect SDF-1 in tumor sections, the polyclonal antibody (no. 22140192 APX; ImmunoKontact, Oxon, UK) was diluted 1:250 and incubated overnight at room temperature. The signal was amplified with the TSA biotin system (Perkin-Elmer Life Science, Boston, MA) following the manufacturer’s instructions.
Morphometric and Statistical Analysis
Necrosis, total tumor area, and number of lung metastases were measured on serial H&E-stained sections at x20 magnification using a Hamamatsu camera connected to a Nikon microscope and analyzed by Scion Image software (Scion Corp., Frederick, MD). CD31- and -SMA-stained tumor and lung sections were evaluated with the AxioCam digital camera attached to the Axioplan 2 microscope (Carl Zeiss AG, Oberkochen, Germany). Calibration of each image and the number and area of blood vessels in the tumor stroma (tumor interior, distant from normal tissue more than 100 µm, x200 magnification), in the tumor periphery (tumor area less than 100 µm distant from the interface with normal tissue, x400 magnification), in the normal tissue/tumor interface (normal tissue comprised within 100 µm from the tumor edge, x400 magnification), and in the pulmonary tissue (x200 magnification) were calculated using the KS300, version 3.0 software (Carl Zeiss AG). Quantification was performed on 10 fields per animal by two independent observers. For tumor section analysis, necrosis and hemorrhage areas were excluded. Results are presented as mean ± SEM. Values were evaluated by the nonparametric Mann-Whitney test; P 
0.05 was considered significant.
Western Blotting Analysis
B16-BL6 melanoma cells in culture were maintained in basal medium containing 0.1% bovine serum albumin for 18 hours and then treated with 100 ng/ml of rmPlGF for 4, 12, and 24 hours. Cell pellets were resuspended in hypotonic buffer (10 mmol/L Tris-HCl, 1 mmol/L ethylenediaminetetraacetic acid, pH 7.4, with protease inhibitor cocktail tablets; Complete, Roche Diagnostics, Basel, Switzerland). An aliquot of extract was saved for determination of protein concentration and the remainder was boiled in the sodium dodecyl sulfate loading buffer. Eighty µg of protein per sample were separated by 6% gel electrophoresis and transferred to a nitrocellulose filter (Amersham Life Science, Buckinghamshire, UK). Protein detection was performed by using a polyclonal antibody against VEGFR-1 (C17, Santa Cruz Biotechnology) that recognizes both the murine and the human form of the receptor, at a concentration of 2 µg/ml, and with a monoclonal antibody against ß-actin diluted 1:1000 (AC-40, Sigma-Aldrich). Detection was performed through a chemiluminescence assay (ECL; Amersham Life Science).
Proliferation Assay
B16-BL6 cells and HUVECs were seeded in 96-well tissue culture dishes at a density of 3 x 103 and 5 x 103cells/well, respectively, in the presence of complete medium. After 24 hours, culture medium was substituted with serum-free medium containing 10, 50, and 100 ng/ml of rmPlGF alone or in combination with 10 ng/ml of rmVEGF. The growth factors were then added every 24 hours. Three days later, the plates were stained with rhodamine B as described25
and the absorbance read at 540 nm in a spectrophotometer (Victor; EG&G Wallac, Turku, Finland). Statistical analysis was performed by the unpaired Student’s t-test; P 0.05 was considered significant.
Peripheral Blood Analysis
Blood was collected and white blood cell counts determined by using a hemocytometer. Plasma samples were obtained and murine PlGF, stem cell factor (SCF), and CXCL12/stromal cell-derived factor 1 (SDF-1) were measured using the Quantikine Kit ELISA (R&D Systems, Eugene, OR). Peripheral blood mononuclear cells were isolated from heparinized blood after centrifugation over a discontinuous gradient using Lymphoprep (Axis-Shield PoC As, Oslo, Norway). Peripheral blood mononuclear cells (6 x 104) were plated in triplicate in a methylcellulose-based colony assay (StemCell Technologies, Vancouver, Canada) containing interleukin-6 and -3 and SCF. Colonies containing granulocyte/macrophage (CFU-GM), granulocyte (CFU-G), and macrophage cells (CFU-M) were scored after 10 days. Values were evaluated by the nonparametric Mann-Whitney test; P 0.05 was considered significant.
Invasion Assay
Eight-µm polycarbonate filters (Nuclepore; Whatman Inc., Clifton, NJ) were coated with 10 µg of Matrigel (BD Biosciences, Bedford, MA). B16-BL6 cells (2 x 105) were introduced in the upper chamber of the Boyden chamber, and graded concentrations of rmPlGF or human fibroblast-conditioned medium were used as stimuli in the lower chamber. After a 3-hour incubation at 37°C, filters were fixed in 4% paraformaldehyde/phosphate-buffered saline and stained in 0.5% crystal violet. Cells from the upper surface were removed by wiping with a cotton swab, and the number of migrating cells attached to the lower surface of the filter was counted in 12 randomly selected microscopic fields (x200 magnification). The invasion index was calculated as the ratio between the number of cells per microscopic field in the experimental condition analyzed and the number of cells per microscopic field in the basal condition (ie, in the absence of any stimulus). Invasion index in the basal condition corresponds to 1. Specificity of rmPlGF-induced stimulation was analyzed by neutralization of the growth factor with a specific antibody (10 µg/ml monoclonal antibody [mAb] 465; R&D Systems) for 45 minutes at room temperature before the invasion test. As a control, an unrelated antibody was used in the same conditions (anti-human VEGF-D mAb 286; R&D Systems). Receptor involvement was analyzed by preincubating the cells with 10 µg/ml of neutralizing polyclonal antibodies anti-mouse VEGFR-1 (AF471; R&D Systems) or anti-mouse VEGFR-2 (AF644; R&D Systems). The invasion assay was performed in the presence of the antibodies. Statistical analysis was performed by the Student’s t-test; P 0.05 was considered significant.
Reverse Transcriptase and Real-Time Polymerase Chain Reaction (Real-Time PCR)
B16-BL6 melanoma cells in culture were exposed to basal medium containing 0.1% bovine serum albumin for 18 hours and then treated with 100 ng/ml of rmPlGF for 3 hours. Total RNA was prepared using an RNeasy Midi kit (Qiagen, Chatsworth, CA) and reverse-transcribed for 50 minutes at 42°C using an oligo (dT)12-18 primer (Invitrogen) and the Superscript II enzyme (Invitrogen). Quantitative real-time PCR was performed using the SYBR Green PCR core reagent mix (Applied Biosystems, Foster City, CA) and gene-specific primers designed using the Primer Express software (Applied Biosystems). The primers used were: VEGFR-1 forward primer 5'-AGCCTACCTCACCGTGCAAG-3' and reverse primer 5'-AAAAGAGGGTCGCAGCCAC-3'; MMP1 forward primer 5'-GGAGACCGGCAAAATGTGG-3' and reverse primer 5'-TGCCCAAGTTGTAGTAGTTTTCCAG-3'; MMP2 forward primer 5'-ATCGCTCAGATCCGTGGTG-3' and reverse primer 5'-TGTCACGTGGTGTCACTGTCC-3'; MMP3 forward primer 5'-GGGATGATGATGCTGGTATGG-3' and reverse primer 5'-GCTTCACATCTTTTGCAAGGC-3'; MMP9 forward primer 5'-AAAACCTCCAACCTCACGGA-3' and reverse primer 5'-GCGGTACAAGTATGCCTCTGC-3'; MMP10 forward primer 5'-GAGA-AATGGACACTTGCACCC-3' and reverse primer 5'-AGGGAGTGGCCAAGTTCATG-3'; MMP13 forward primer 5'-CAAATGGTCCCAAACGAACTTAAC-3' and reverse primer 5'-CCACTTCAGAATGGGACATATC-AG-3'. The reaction conditions were as follows: 2 minutes at 50°C (one cycle), 10 minutes at 95°C (one cycle), 15 seconds at 95°C, and 1 minute at 60°C (40 cycles). Gene-specific PCR products were continuously measured by means of the ABI Prism 5700 detection system (Perkin-Elmer, Norwalk, CT) and quantified with a gene-specific standard curve. Value normalization was performed by using a GAPDH standard curve (forward primer 5'-GTATGACTCCACTCACGGCAAA-3' and reverse primer 5'-TTCCCATTCTCGGCCTTG-3'). Results are expressed as the relative fold increase of the PlGF-stimulated over the control group, which was used as a calibrator.
Zymography
B16-BL6 cells were seeded in 100-mm dishes at a density of 2.5 x 103 cells/cm2 in the presence of complete medium. After 24 hours, culture medium was substituted with either serum-free alone or serum-free medium containing 20 and 100 ng/ml of PlGF, and cells were maintained at 37°C for a further 24 hours. Conditioned media were collected and concentrated using Centricon YM-10 concentrators (Amicon Bioseparations; Millipore Corp., Bedford, MA). Protein content was determined by the Bradford assay (Bio-Rad, Hercules, CA). Thirty-five-µl aliquots were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis in 8% polyacrylamide gels containing 0.1% gelatin under nonreducing conditions, washed first in renaturing buffer (2.7% Triton X-100) and then in a developing buffer (50 mmol/L Tris-HCl, 200 mmol/L NaCl, 10 mmol/L CaCl2, pH 7.5) for 30 minutes, and left in the same buffer overnight at 37°C. Gels were stained with Coomassie brilliant blue R-250 (Bio-Rad) and destained with 5% methanol and 7% acetic acid. A semiquantitative analysis of MMP-2 and MMP-9 activity was performed in triplicate by densitometric methods using Fluor S Max Multi Imager (Bio-Rad), and intensity for each band was expressed as uncalibrated optical density (OD).
|
Results |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
To establish the role of PlGF in promoting tumor growth in vivo, B16-BL6 melanoma cells were injected intradermally into the flank of K14-PlGF transgenic mice and WT littermates (n = 9). Tumor size was measured daily starting from day 15 after injection, when the tumor mass began to be detectable in both transgenic and control animals. Mice were sacrificed 25 days after cell injection. As shown in Figure 1A
, in K14-PlGF mice tumors grew exponentially throughout time with dramatic growth acceleration as compared with tumors in WT animals. A significant difference was already detectable at day 15 after cell injection. At day 25, there was a more than fivefold increase in tumor volume in K14-PlGF mice compared to WT littermates. Macroscopic analysis of tumors dissected from the transgenic animals revealed that the melanoma mass was surrounded by an extended area of prominent vascularization (Figure 1B)
.
|
. At the protein level, VEGFR-1 production was analyzed through Western blotting of B16-BL6 cell extract using an antibody specific for the C-terminal portion of the receptor (Figure 2B)
. HUVEC extract was used as a positive control and showed two bands corresponding to glycosylated and unglycosylated forms of VEGFR-1.26
B16-BL6 cells showed only one band that was also observed in human melanoma cells27
and corresponded to the un-glycosylated state. M14 human melanoma cells were used as a negative control because they do not express VEGFR-1.6
We treated B16-BL6 cells with 100 ng/ml of rmPlGF for 4, 12, and 24 hours, but no significant increase in VEGFR-1 protein expression was observed in Western blotting analysis (Figure 2B)
. Then we treated melanoma cells in vitro for 3 days with rmPlGF alone or in combination with rmVEGF. None of these stimuli determined an increase in cell proliferation (Figure 2C)
, indicating that PlGF did not directly influence the growth rate of B16-BL6 cells. HUVECs were used as a positive control in the proliferation assay and significantly responded to either rmPlGF alone (100 ng/ml) or in combination with rmVEGF (10 ng/ml) (Figure 2C)
when compared to untreated cells.
|
Microscopically, tumors grown both in transgenic and WT animals appeared as masses of atypical cells located in the dermis and hypodermis. In most cases, the tumor was separated from the overlying epidermis by a thin zone of dermis that appeared highly vascularized (Figure 3A)
. Occasionally, the skin above the melanoma mass was ulcerated, but ulceration did not correlate with a more aggressive phenotype and subsequent development of metastases. Tumor cells were large with eosinophilic cytoplasm often containing accumulation of melanin pigment and atypical vesicular nuclei with prominent nucleoli. Mitotic figures were frequently observed (Figure 3B)
. No significant inflammatory infiltrate, in particular macrophages/monocytes, was detected within the lesions. Computer-assisted image analysis of H&E-stained tumor sections was used to measure the amount of necrotic tissue present within the tumor. Despite dramatic acceleration in tumor growth in transgenic mice, a similar percentage of necrosis was observed in tumors of transgenic and WT animals (Figure 3C)
. Consequently, the area of residual viable tumor was significantly larger in the K14-PlGF compared to WT mice (Figure 3D)
.
|
. On the other hand, total vessel area was significantly larger at the tumor periphery (11 ± 1% versus 7 ± 0.5%) in transgenic compared to WT mice, mainly because of the increment in vessel size (721 ± 134 µm2 versus 382 ± 81 µm2). Transgenic animals also displayed a marked increase of the vascular area at the interface between normal tissue and tumor (24 ± 4% versus 7 ± 1%), where both vessel density (272 ± 64 vessels/mm2 versus 117 ± 17 vessels/mm2) and vessel size (833 ± 235 µm2 versus 321 ± 96 µm2) were augmented (Figure 4)
. Using the anti-SMA antibody, larger vessels (7412 ± 1196 µm2 versus 3593 ± 897 µm2), leading to a superior vascular area (7 ± 1% versus 2 ± 0.6%), were detected only in the interior of tumors grown in transgenic mice.
|
In a separate set of experiments we investigated whether the high amount of PlGF normally present in the serum of K14-PlGF mice could promote HSC mobilization from the bone marrow. A colony-forming assay was performed on peripheral blood mononuclear cells obtained from WT and transgenic mice (n = 10) and a significantly higher number of colony-forming units could be detected in the K14-PlGF animal-derived samples (Figure 5A)
.
|
30
are two cytokines implicated in the regulation of HSC trafficking, and we evaluated their amount in plasma samples from transgenic and WT mice (n = 10). No significant difference in SCF or SDF-1 plasma levels could be detected between the two animal types (data not shown). SDF-1 was reported to be induced by VEGF and to act by retaining HSCs in close proximity to angiogenic vessels.7
To investigate whether PlGF could also augment SDF-1 expression in vivo, we analyzed tumor sections from transgenic and WT mice. In eight of nine tumors grown in transgenic animals, specific SDF-1 staining was detected in clusters of melanoma cells scattered in the tumor mass (Figure 5B)
. A similar staining pattern was present in a lower number of tumors from WT mice (five of nine samples). PlGF Leads to Increased Metastatic Spread
Lungs of tumor-bearing mice were macroscopically inspected for the presence of metastatic nodules. Six of nine K14-PlGF mice developed spontaneous pulmonary metastases within 25 days from tumor cell inoculation, whereas metastases were present in only one of nine WT mice. In addition, analysis of lung sections (Figure 6A)
showed that the average number and area of lung metastases were significantly higher in K14-PlGF than in control mice (Figure 6B)
.
|
. To verify whether the increased lung vessel area could facilitate metastasis formation, we induced experimental pulmonary metastases by injecting B16-BL6 melanoma cells intravenously in seven WT and eight transgenic mice. After 2 weeks, metastases were detected in six of eight animals in the transgenic mice group and in one of seven animals in the WT group. Analysis of metastatic foci in the lungs showed that the mean number of metastases in transgenic mice was significantly higher than controls (6 ± 2.07 versus 1 ± 0.87, P < 0.05). PlGF Facilitates B16-BL6 Melanoma Cells Invasion
We then investigated whether PlGF could directly promote B16-BL6 melanoma cell invasiveness. Using a Boyden chamber-based assay, we observed that PlGF supported melanoma cell invasion in a dose-dependent manner (Figure 7A)
. The specificity of PlGF-induced invasion was confirmed by using a monoclonal antibody against PlGF that significantly inhibited cell migration, whereas an unrelated monoclonal antibody had no effect (Figure 7B)
. The blocking effect of anti-PlGF antibody was specific, because it had no effect on invasion rate induced by a different stimulus such as human fibroblast-conditioned medium (Figure 7C)
. Furthermore, treatment of B16-BL6 cells with a polyclonal antibody that selectively blocks VEGFR-1 inhibited cell invasion (Figure 7D)
whereas a blocking antibody directed against VEGFR-2 had a modest, although significant, effect (Figure 7D)
. These data confirmed the involvement of VEGFR-1 in mediating the PlGF effect on B16-BL6 cell invasion.
|
, the treatment with PlGF did not affect the amount of RNA coding for the two gelatinases, the two collagenases, or the stromelysin MMP-10 but slightly augmented the RNA coding for MMP-3. We also searched for a link between gelatinase activation and constant exposure of melanoma cells to high levels of PlGF in transgenic animals. Gelatin zymography of B16-BL6 cell-conditioned medium (Figure 8B)
showed a dose-dependent increase in the release of activated MMP-2 (66 kd) and MMP-9 (86 kd) after a 24-hour stimulation with PlGF (Figure 8, C–D)
.
|
|
Discussion |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
We could also verify that the high amount of PlGF in the serum of transgenic mice leads to augment circulating HSCs potentially contributing to tumor angiogenesis. These data are in keeping with the previously reported role of PlGF in mobilization of HSCs from the bone marrow.13,37
PlGF restores the early phase of hematopoiesis after bone marrow suppression through direct chemotaxis of VEGFR-1-positive progenitor cells and the late phase of hematopoietic recovery through MMP-9-mediated release of SCF.13
In K14-PlGF transgenic animals, we did not observe a significant increment in SCF plasma levels, suggesting that mobilization of HSCs is achieved by direct PlGF-mediated chemotaxis or through a different SCF-independent mechanism. Growing evidence indicates that SDF-1 is implicated in the regulation of HSC trafficking from the bone marrow to circulation and tissues38
and in retaining HSCs in close proximity to newly forming vessels where they could produce angiogenic cytokines or directly differentiate into endothelial cells.7
We could not detect significant differences in the amount of SDF-1 present in plasma samples of WT and transgenic mice. However, a subpopulation of melanoma cells, in particular in transgenic animals, expresses SDF-1 in vivo and might contribute in local HSC recruitment. No data are so far available about a direct co-operation between PlGF and SDF-1 in HSC mobilization, but VEGF seems to modulate the mRNA levels of SDF-1.7,39
Based on our results, a similar involvement of PlGF may be hypothesized. In this context, PlGF-mediated mobilization of precursor cells together with PlGF induction of SDF-1 expression in the tumor might indirectly contribute to tumor angiogenesis.
Besides affecting tumor growth through local stimulation of angiogenesis, PlGF seems to be involved in metastatic spreading. In our study, the number and area of lung metastases are strongly enhanced in K14-PlGF transgenic animals. PlGF induces a high vascularization of the tumor tissue, thus indirectly facilitating the entrance of melanoma cells into the blood flow and further spreading. We provide evidence that the amount of PlGF present in the blood of transgenic animals is sufficient to augment distal organ vascularization, favoring tissue colonization by metastatic cells. In fact, intravenous inoculation of melanoma cells leads to formation of a greater number of lung metastases in transgenic mice compared to WT littermates. PlGF can also act on VEGFR-1-expressing melanoma cells by increasing their invasion capability. Melanoma cells stimulated in vitro with PlGF show a higher mobility rate through the extracellular matrix that is dependent on VEGFR-1 activation because cell treatment with a function-blocking antibody against VEGFR-1 inhibits their migration toward PlGF. An antibody specific for VEGFR-2 had a minor but significant effect on cell invasion, suggesting a contribution of VEGFR-2 signaling pathways, possibly through a mechanism that involves cross talk between the two VEGF receptors.14 Finally, we demonstrate a consistent increase in secretion of active MMP-2 and MMP-9 after B16-BL6 cell treatment with PlGF. A positive correlation between tumor progression and release of MMP-2 and -9 has been demonstrated in numerous studies,40-42 and our findings suggest that PlGF could take part in activating specific MMPs.
In conclusion, using a syngeneic animal model of melanoma growth, we characterized the broad role of PlGF in melanoma angiogenesis and progression in an immunocompetent host. Our data indicate that a therapeutic action directed to specific inhibition of PlGF could represent a promising tool to counteract metastatic diffusion of the primary tumor. Moreover, injection of tumor cells in our transgenic mouse model could be a valuable system to test the effects of specific anti-PlGF therapeutic compounds on tumor growth and metastasis formation.
|
Acknowledgements |
|---|
|
Footnotes |
|---|
Supported by the Italian Ministry of Health (grant RF228).
M.M. and N.D.L. contributed equally to this work.
Accepted for publication April 20, 2006.
|
References |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
5ß1 integrin. J Cell Sci 2003, 116:3479-3489This article has been cited by other articles:
 |
|
 |
|
  M. Kerber, Y. Reiss, A. Wickersheim, M. Jugold, F. Kiessling, M. Heil, V. Tchaikovski, J. Waltenberger, M. Shibuya, K. H. Plate, et al. Flt-1 Signaling in Macrophages Promotes Glioma Growth In vivo Cancer Res., September 15, 2008; 68(18): 7342 - 7351. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Sini, I. Samarzija, F. Baffert, A. Littlewood-Evans, C. Schnell, A. Theuer, S. Christian, A. Boos, H. Hess-Stumpp, J. A. Foekens, et al. Inhibition of Multiple Vascular Endothelial Growth Factor Receptors (VEGFR) Blocks Lymph Node Metastases but Inhibition of VEGFR-2 Is Sufficient to Sensitize Tumor Cells to Platinum-Based Chemotherapeutics Cancer Res., March 1, 2008; 68(5): 1581 - 1592. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Schomber, L. Kopfstein, V. Djonov, I. Albrecht, V. Baeriswyl, K. Strittmatter, and G. Christofori Placental Growth Factor-1 Attenuates Vascular Endothelial Growth Factor-A Dependent Tumor Angiogenesis during {beta} Cell Carcinogenesis Cancer Res., November 15, 2007; 67(22): 10840 - 10848. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. N. Kaplan, S. Rafii, and D. Lyden Preparing the "Soil": The Premetastatic Niche Cancer Res., December 1, 2006; 66(23): 11089 - 11093. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
